STOCK TITAN

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Puma Biotechnology (NASDAQ: PBYI) will host a conference call on November 3, 2022, at 1:30 p.m. PDT to discuss its third quarter financial results. Interested parties can access the call via telephone or through a live webcast on the company’s website. Puma's NERLYNX (neratinib) has been approved for treating early-stage HER2-overexpressed breast cancer and advanced HER2-positive breast cancer. In September 2022, Puma secured an exclusive license for alisertib, aiming to develop it for small cell lung cancer and breast cancer.

Positive
  • Puma secured an exclusive license for alisertib, expanding its oncology portfolio.
  • NERLYNX is approved for multiple indications, enhancing revenue potential.
Negative
  • None.

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 3, 2022, following the release of its third quarter 2022 financial results.

The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay will be available shortly after completion of the call and will be archived on Puma’s website for 90 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com

David Schull or Olipriya Das, Russo Partners, +1 212 845 4200

david.schull@russopartnersllc.com

olipriya.das@russopartnersllc.com

Source: Puma Biotechnology, Inc.

FAQ

When will Puma Biotechnology release their third-quarter results?

Puma Biotechnology will release their third-quarter results on November 3, 2022.

How can I access the Puma Biotechnology conference call?

The conference call can be accessed by dialing 1-877-709-8150 for domestic calls or 1-201-689-8354 for international calls.

What drugs does Puma Biotechnology focus on?

Puma Biotechnology focuses on the development of NERLYNX (neratinib) and the newly licensed drug alisertib.

What is the purpose of the conference call on November 3, 2022?

The purpose of the conference call is to discuss Puma Biotechnology's third-quarter financial results.

PUMA BIOTECHNOLOGY INC

NASDAQ:PBYI

PBYI Rankings

PBYI Latest News

PBYI Stock Data

139.80M
38.59M
15.14%
67.8%
6.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LOS ANGELES